Literature DB >> 10369877

Structural and functional rescue of murine rod photoreceptors by human rhodopsin transgene.

N McNally1, P Kenna, M M Humphries, A H Hobson, N W Khan, R A Bush, P A Sieving, P Humphries, G J Farrar.   

Abstract

Mice carrying a targeted disruption of the rhodopsin gene develop a severe degenerative retinopathy, failing to elaborate rod photoreceptor outer segments (ROS), having no recordable rod electroretinogram (ERG) and losing all of their rod cells over a period of approximately 12 weeks. Murine and human rhodopsins differ in their amino acid sequences. Whether, or to what extent, such variability might influence the ability of human rhodopsin to serve as an adequate structural and functional substitute for the endogenous protein in mouse rod cells bears direct relevance to exploiting the full utility of Rho-/-animals as a model of degenerative retinal disease in man. We crossed Rho-/-mice with mice expressing a wild-type human rhodopsin transgene at levels approximating to those of the endogenous protein. Immunohistological examination of retinal selections from such animals demonstrated ROS of normal number and length and temporal expression of rhodopsin similar to that observed in wild-type animals; that is, immunoreactivity to an anti-rhodopsin antibody became clearly evident by day 3 post-partum. Whereas Rho-/-mice never display a rod ERG response, and even lose cone responses by 12 weeks of age, rescued mice showed 75% normal maximum amplitudes and had ERG b-wave thresholds (based on a 50 microV criterion) within 0.1 log unit of normal wild-type at 20 weeks, and cone amplitudes remained normal at this age. These data demonstrate very substantial structural and functional rescue of the rod photoreceptors of Rho-/-mice and long-term preservation by the human rhodopsin transgene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369877     DOI: 10.1093/hmg/8.7.1309

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

Review 1.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

2.  Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy.

Authors:  Naomi Chadderton; Sophia Millington-Ward; Arpad Palfi; Mary O'Reilly; Gearóid Tuohy; Marian M Humphries; Tiansen Li; Peter Humphries; Paul F Kenna; G Jane Farrar
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

3.  Rhodopsin Genomic Loci DNA Nanoparticles Improve Expression and Rescue of Retinal Degeneration in a Model for Retinitis Pigmentosa.

Authors:  Min Zheng; Rajendra N Mitra; Ellen R Weiss; Zongchao Han
Journal:  Mol Ther       Date:  2019-12-14       Impact factor: 11.454

4.  Imaging translucent cell bodies in the living mouse retina without contrast agents.

Authors:  A Guevara-Torres; D R Williams; J B Schallek
Journal:  Biomed Opt Express       Date:  2015-05-18       Impact factor: 3.732

5.  Rhodopsin C terminus, the site of mutations causing retinal disease, regulates trafficking by binding to ADP-ribosylation factor 4 (ARF4).

Authors:  Dusanka Deretic; Andrew H Williams; Nancy Ransom; Valerie Morel; Paul A Hargrave; Anatol Arendt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

6.  Constitutive "light" adaptation in rods from G90D rhodopsin: a mechanism for human congenital nightblindness without rod cell loss.

Authors:  P A Sieving; M L Fowler; R A Bush; S Machida; P D Calvert; D G Green; C L Makino; C L McHenry
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

7.  Mislocalization and degradation of human P23H-rhodopsin-GFP in a knockin mouse model of retinitis pigmentosa.

Authors:  Brandee A Price; Ivette M Sandoval; Fung Chan; David L Simons; Samuel M Wu; Theodore G Wensel; John H Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-28       Impact factor: 4.799

Review 8.  On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention.

Authors:  G Jane Farrar; Paul F Kenna; Peter Humphries
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

Review 9.  The nature of dominant mutations of rhodopsin and implications for gene therapy.

Authors:  John H Wilson; Theodore G Wensel
Journal:  Mol Neurobiol       Date:  2003-10       Impact factor: 5.590

10.  RNA interference-mediated suppression and replacement of human rhodopsin in vivo.

Authors:  Mary O'Reilly; Arpad Palfi; Naomi Chadderton; Sophia Millington-Ward; Marius Ader; Thérèse Cronin; Thérèse Tuohy; Alberto Auricchio; Markus Hildinger; Amanda Tivnan; Niamh McNally; Marian M Humphries; Anna-Sophia Kiang; Pete Humphries; Paul F Kenna; G Jane Farrar
Journal:  Am J Hum Genet       Date:  2007-05-23       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.